Karbapenemlerin ve Monobaktamların Etki Spektrumu ve Kullanım Alanları

Drusano GL. An overview of the pharmacology of imipenem/cilastatin. The Journal of antimicrobial chemotherapy 1986;18 Suppl E:79-92. doi: 10.1093/jac/18.supplement_e.79.

Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrobial agents and chemotherapy 2011;55:4943-60. doi:10.1128/AAC.00296-11

Armstrong T, Fenn SJ, Hardie KR. JMM Profile: Carbapenems: a broad-spectrum antibiotic. J Med Microbiol. 2021;70(12):001462. doi:10.1099/jmm.0.001462

Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52. doi:10.2165/00003495-200767070-00006

Fritsche TR, Sader HS, Stillwell MG, et al. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). Diagnostic microbiology and infectious disease 2009;63:440-6. doi: 10.1016/j.diagmicrobio.2009.01.019

Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrobial agents and chemotherapy 2012;56:3603-9. doi: 10.1128/AAC.00326-12

Mera RM, Miller LA, Amrine-Madsen H, et al. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microbial drug resistance (Larchmont, NY) 2010;16:209-15. doi:10.1089/mdr.2010.0052

Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrobial agents and chemotherapy 2002;46:1136-40. doi: 10.1128/AAC.46.4.1136-1140.2002

Cercenado E, Marín M, Sánchez-Martínez M, et al. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrobial agents and chemotherapy 2007;51:1102-4. doi: 10.1128/AAC.01102-06

Chavan VV, Dalal A, Nagaraja S, et al. Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLoS One. 2020;15(6):e0234651. Published 2020 Jun 16. doi:10.1371/journal.pone.0234651

Zumla A. Mandell, Douglas, and Bennett's principles and practice of infectious diseases: The Lancet. Infectious Diseases, 2010 May;10(5):303-4. doi: 10.1016/S1473-3099(10)70089-X. Epub 2010 Apr 21.

Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. The Journal of antimicrobial chemotherapy 2014;69:2043-55. doi: 10.1093/jac/dku111

Shayan M, Elyasi S. Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review. Expert opinion on drug safety. 2020;19(8):999-1010. doi:10.1080/14740338.2020.1796967

Paterson DL, Depestel DD. Doripenem. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49:291-8. doi:10.1086/600036

FDA. FDA Drug Safety Communication: FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. 2014. http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm. 2014. (erişim tarihi: 12/12/2022)

Prescott WA, Jr., DePestel DD, Ellis JJ, et al. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38:1102-7. doi:10.1086/382880

Sodhi M, Axtell SS, Callahan J, et al. Is it safe to use carbapenems in patients with a history of allergy to penicillin? The Journal of antimicrobial chemotherapy 2004;54:1155-7. doi:10.1093/jac/dkh454

Cunha BA, Hamid NS, Krol V, et al. Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. Journal of chemotherapy (Florence, Italy) 2008;20:233-7. doi:10.1179/joc.2008.20.2.233

Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014;59:1113-22. doi:10.1093/cid/ciu587

Romano A, Viola M, Guéant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins. The New England journal of medicine 2006;354:2835-7. doi:10.1056/NEJMc053529

Romano A, Viola M, Guéant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Annals of internal medicine 2007;146:266-9. doi:10.7326/0003-4819-146-4-200702200-00005

Miller AD, Ball AM, Bookstaver PB, et al,. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011;31:408-23. doi:10.1592/phco.31.4.408

Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. Jama 2018;319:788-99. doi:10.1001/jama.2018.0438

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious diseases and therapy 2018;7:439-55. doi:10.1007/s40121-018-0214-1

Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC microbiology 2019;19:150. doi:10.1186/s12866-019-1522-7

Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020;70:1799-808. doi:10.1093/cid/ciz530

Kishiyama JL, Adelman DC. The cross-reactivity and immunology of beta-lactam antibiotics. Drug safety 1994;10:318-27. doi:10.2165/00002018-199410040-00006

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021;72:e169-e83. doi:10.1093/cid/ciac268

Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2022;28:521-47.